PP
DGX icon

Paloma Partners’s Quest Diagnostics DGX Stock Holding History

Paloma Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19,500
Closed -$3.05M – 795
2022
Q4 		$3.05M Buy
+19,500
New +$2.8M 0.14% 135
2018
Q1 		– Sell
-69,900
Closed -$6.88M – 2007
2017
Q4 		$6.88M Buy
69,900
+51,000
+270% +$4.83M 0.09% 184
2017
Q3 		$1.77M Buy
+18,900
New +$2.01M 0.02% 828

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Paloma Partners's DGX Position: Q2 2025 in Review

Paloma Partners sold out of Quest Diagnostics (DGX) in Q2 2025, closing a stake of 1,993 shares — an estimated $337K sold.

Paloma Partners first reported a position in DGX in Q3 2013 and held it in 30 quarters. The position peaked at $6.34M in Q3 2021. 991 funds tracked by Wall St. Rank hold DGX as of Q2 2025.

  • Paloma Partners reported no remaining Quest Diagnostics position as of Q2 2025 after selling out during the quarter.
  • Paloma Partners sold 1,993 Quest Diagnostics shares in Q2 2025, an estimated $337K.
  • Paloma Partners first reported a position in Quest Diagnostics in Q3 2013 and held it in 30 quarters.
  • Paloma Partners's Quest Diagnostics position peaked at $6.34M in Q3 2021.
  • 991 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2025.

Based on Paloma Partners's 13F filing for Q2 2025, filed 14 Aug 2025.